It is well known that there are substantial challenges for the development and clinical supply of Advanced Therapy Medicinal products (ATMP).  These  span many different themes: complex regulatory pathways; unfamiliar clinical procurement practices; novel biology; limited data to justify reimbursement; high cost of goods, to name just a few. As such it is important for developers of ATMPs to consider these challenges earlier than might be expected for the developers of traditional pharmaceutics. However, a supportive ecosystem will act to further aid developers and hopefully accelerate product development, trial and ultimately licensure.  This talk will describe some of the initiatives the UK government have invested in to support the development of an ecosystem to accelerate the uptake of these potential life-changing therapies.